新型pyrazolo[3,4-d]pyrimidine基衍生物的设计,合成和抗癌评估:CDK2抑制,诱导亡的活性,分子建模研究
Rasha A Hassan1, Hanan H Kadry1, Radwa G Sayed2
1Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.
Bioorganic & medicinal chemistry
|June 24, 2025
概括
新的pyrazolo[3,4-d]pyrimidine衍生物通过抑制CDK2.2表现出强大的抗癌活性. 化合物3d在癌细胞中表现出显著的抗增殖作用和诱导亡,突显了其治疗潜力.
科学领域:
- 药用化学 医学化学
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 癌症仍然是全球主要的死亡原因,需要开发新的治疗药物.
- 循环素依赖激酶2 (CDK2) 是细胞循环的关键调节剂,其失调与各种癌症有关.
- 抑制CDK2通路为抗癌药物开发提供了一个有前途的战略.
研究的目的:
- 为了合成和评估新的pyrazolo[3,4-d]pyrimidine衍生物作为潜在的抗癌剂.
- 研究这些化合物对CDK2酶通路的抑制作用.
- 评估各种人类癌症细胞系中的抗增殖活性和作用机制.
主要方法:
- 合成了三系列的pyrazolo[3,4-d]pyrimidine衍生物.
- 在国家癌症研究所 (NCI) 对60个人类癌症细胞系进行抗癌活性查.
- 酶抑制试验 (CDK2/CyclinA2),亡诱导研究,细胞周期分析,分子对接和分子动力学模拟.
主要成果:
- 化合物3d在大多数测试的癌症细胞系中表现出强大的抗增殖活性,具有亚微分子GI50值.
- 化合物3d显示出对脏A498细胞系的高选择性和有效性,诱导细胞亡和S相细胞周期停止.
- 化合物3d和3e有效抑制了CDK2/CyclinA2,分子研究证实了3d与CDK2活性部位的稳定结合.
结论:
- 皮拉佐[3,4-d]胺衍生物,特别是化合物3d,作为向CDK2通路的抗癌剂,显示出显著的希望.
- 化合物3d在癌细胞中诱导细胞亡和细胞循环停止的能力需要进一步研究以开发治疗方法.
- 这些发现支持继续探索这种化学支架,用于新瘤治疗.
相关概念视频
01:28Structure-Activity Relationships and Drug Design
1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
02:15M-Cdk Drives Transition Into Mitosis
5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K